^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Neuroblastoma
    Drug:Iwilfin (eflornithine) (Ornithine decarboxylase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    12/13/2023
    Excerpt:
    IWILFIN is an ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.